Akebia Therapeutics (AKBA) vs Genelux (GNLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Genelux (GNLX) has outperformed Akebia Therapeutics (AKBA) over the past year, losing 56.3% versus a loss of 75.1%. Akebia Therapeutics is the larger company by market cap ($107.0 million vs $103.4 million), about 1.0 times the size. Akebia Therapeutics converts more of its revenue into profit, with a net margin of -2.3% versus -401812.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | GNLX |
|---|---|---|
| Share price | $0.3855 | $2.17 |
| Market cap | $107.04M | $103.36M |
| 1-day change | -8.71% | -4.82% |
| YTD return | -76.06% | -50.23% |
| 1-year return | -75.13% | -56.25% |
| 5-year return | -85.56% | — |
| EPS (TTM) | $-0.17 | $-0.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $236.20M | $8.00K |
| Revenue growth (YoY) | +47.46% | 0.00% |
| Net income (latest FY) | $-5.34M | $-32.15M |
| Gross margin | 83.29% | — |
| Operating margin | 9.95% | -415175.00% |
| Net margin | -2.26% | -401812.50% |
| 52-week high | $1.73 | $5.89 |
| 52-week low | $0.361 | $1.77 |
| Distance from 52-week high | -77.72% | -63.16% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +678.21% | +767.74% |
| Average volume | 8.05M | 333.31K |
| Shares outstanding | 277.66M | 47.63M |
| Employees | 194 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GNLX has outperformed AKBA by 18.9 percentage points over the past year.
- Akebia Therapeutics is more profitable, keeping -2.3 cents of every revenue dollar as net income versus -401812.5 cents for Genelux.
- Akebia Therapeutics grew revenue faster in its latest fiscal year (+47.46% vs 0.00%).
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
AKBA vs GNLX FAQ
Which is bigger, Akebia Therapeutics or Genelux?
Akebia Therapeutics (AKBA) is larger, with a market capitalization of $107.04M compared with $103.36M for Genelux (GNLX).
Which stock has performed better over the past year, AKBA or GNLX?
GNLX returned -56.25% over the past 12 months, compared with -75.13% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Genelux in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.